Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents.
10.11005/jbm.2016.23.2.85
- Author:
Sungjun KIM
1
;
Hyun Hee BANG
;
Hanna YOO
;
Il Hyung PARK
;
Kyu Hyun YANG
;
Hyunsun LIM
;
Woo Seok JUNG
Author Information
1. Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Alendronate;
Bone density;
Femur;
Risedronate
- MeSH:
Absorptiometry, Photon;
Alendronate;
Body Mass Index;
Bone Density*;
Femur;
Follow-Up Studies;
Hip;
Humans;
Retrospective Studies;
Risedronate Sodium
- From:Journal of Bone Metabolism
2016;23(2):85-93
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: To retrospectively assess whether the response of subtrochanteric lateral cortex (STLC) is different according to the bisphosphonate agents in terms of bone mineral density (BMD) change. METHODS: A total of 149 subjects, who had 2- to 4-year interval follow-up of BMD using dual energy X-ray absorptiometry (DXA), were included in this retrospective study divided into following 3 groups: control group (no consumption of any anti-osteoporotic drugs, n=38), alendronate group (naïve alendronate users, n=48), risedronate group (naïve risedronate users, n=63). BMD was measured at the STLC and subtrochanteric medial cortex (STMC) in each patient by drawing rectangular ROIs at the bone cortices. The percent change of BMD at the STLC were compared between the aforementioned 3 groups by using analysis of covariance model to control five independent variables of age, body mass index, percent change of STMC, hip axis length, time interval between DXA examinations. RESULTS: The least square mean values±standard deviation of the percent change of BMD in the control, alendronate, and risedronate groups were 1.46±1.50, 2.23±1.26, and 6.96±1.11, respectively. The risedronate group showed significantly higher change of BMD percentage compared with the control (adjusted P=0.012) or alendronate (adjusted P=0.016) groups. CONCLUSIONS: The percent change of BMD at the STLC in the risedronate user group was greater than the alendronate and control groups. The implication of these changes needs to be further verified.
